Stonegate Investment Group’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $445K | Hold |
49,688
| – | – | 0.01% | 254 |
|
|
2025
Q1 | $373K | Hold |
49,688
| – | – | 0.01% | 250 |
|
|
2024
Q4 | $374K | Buy |
49,688
+100
| +0.2% | +$752 | 0.01% | 245 |
|
|
2024
Q3 | $377K | Hold |
49,588
| – | – | 0.01% | 259 |
|
|
2024
Q2 | $306K | Hold |
49,588
| – | – | 0.01% | 259 |
|
|
2024
Q1 | $252K | Buy |
49,588
+600
| +1% | +$3.05K | 0.01% | 276 |
|
|
2023
Q4 | $293K | Hold |
48,988
| – | – | 0.01% | 252 |
|
|
2023
Q3 | $347K | Hold |
48,988
| – | – | 0.01% | 227 |
|
|
2023
Q2 | $345K | Hold |
48,988
| – | – | 0.01% | 235 |
|
|
2023
Q1 | $409K | Hold |
48,988
| – | – | 0.02% | 222 |
|
|
2022
Q4 | $562K | Hold |
48,988
| – | – | 0.02% | 194 |
|
|
2022
Q3 | $617K | Hold |
48,988
| – | – | 0.03% | 164 |
|
|
2022
Q2 | $518K | Hold |
48,988
| – | – | 0.02% | 182 |
|
|
2022
Q1 | $797K | Hold |
48,988
| – | – | 0.03% | 141 |
|
|
2021
Q4 | $678K | Buy |
+48,988
| New | +$678K | 0.03% | 154 |
|